BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hachim A, Kavian N, Valkenburg SA. Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets. Curr Opin Virol 2021;50:139-46. [PMID: 34464844 DOI: 10.1016/j.coviro.2021.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Giron CC, Laaksonen A, Barroso da Silva FL. Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2095305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bertoletti A, Iannacone M. Editorial overview: Viral pathogenesis. Curr Opin Virol 2022;55:101253. [PMID: 35810670 DOI: 10.1016/j.coviro.2022.101253] [Reference Citation Analysis]
3 Gori Savellini G, Anichini G, Gandolfo C, Cusi MG. Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 Secretion. Viruses 2022;14:1273. [PMID: 35746745 DOI: 10.3390/v14061273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hachim A, Gu H, Kavian O, Mori M, Kwan MYW, Chan WH, Yau YS, Chiu SS, Tsang OTY, Hui DSC, Mok CKP, Ma FNL, Lau EHY, Amarasinghe GK, Qavi AJ, Cheng SMS, Poon LLM, Peiris JSM, Valkenburg SA, Kavian N. SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nat Commun 2022;13:2951. [PMID: 35618731 DOI: 10.1038/s41467-022-30699-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Altmann DM, Boyton RJ. COVID-19 vaccination: The road ahead. Science 2022;375:1127-32. [PMID: 35271316 DOI: 10.1126/science.abn1755] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 32.0] [Reference Citation Analysis]
6 Giron CC, Laaksonen A, da Silva FLB. Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies.. [DOI: 10.1101/2022.01.29.478316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nguyen THO, Cohen CA, Rowntree LC, Bull MB, Hachim A, Kedzierska K, Valkenburg SA. T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants. Front Med (Lausanne) 2021;8:793102. [PMID: 35004764 DOI: 10.3389/fmed.2021.793102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]